In the UK, GLP-1 receptor agonists are approved as third line treatment for patients with T2D with a BMI of ≥ 35 kg/m2 and specific psychological or other medical problems associated with obesity; or with a BMI < 35 kg/m2 if insulin therapy would have significant occupational implications, or weight loss would benefit other obesity-related comorbidities [23]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.